An additional approval for ATTR-CM could potentially more than double the peak-year sales potential of patisiran. Under the name Onpattro, the drug racked up $137.009 million in first-quarter net product revenues, up 34% from $101.951 million in Q1 2021, on top of $474.737 million for all of 2021, (up 55% from $306.081 million in 2020). Alnylam is among companies developing ATTR treatments that they hope will someday outcompete Pfizer’s blockbusters of Vyndaqel® (tafamidis meglumine) and/ Vyndamax® (tafamidis . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Alnylam Basks in the Glow of Heart Drug’s Phase III Success appeared first on GEN – Genetic Engineering and Biotechnology News.
